Atrial Fibrillation Treatment Using Flecainide and Elevated Potassium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atrial fibrillation (AF) are inadequate in efficacy, timing, and safety, particularly for persistent or sustained AF, due to reduced effectiveness of sodium channel blockers caused by hyperpolarized resting membrane potentials.
Innovation Solution
Administering a sodium channel blocker in combination with a mild elevation of extracellular potassium levels, either before or simultaneously, to enhance the blocking effect and improve cardioversion of AF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a sodium channel blocker is administered alone, then the treatment is simple, but the efficacy of AF termination is insufficient
Solution Approach 1:
The patent combines a sodium channel blocker with a potassium channel blocker in a single treatment regimen. The sodium channel blocker (e.g., flecainide, propafenone) and potassium channel blocker (e.g., ibutilide, dofetilide) work synergistically to terminate atrial fibrillation, with the potassium channel blocker enhancing the effectiveness of the sodium channel blocker by modifying repolarization and increasing sodium channel availability.
Solution Approach 2:
The treatment uses a composite pharmacological approach combining two different classes of antiarrhythmic drugs (Class IC sodium channel blockers and Class III potassium channel blockers) to achieve superior AF termination efficacy compared to monotherapy, leveraging the complementary mechanisms of action of both drug classes.
2Loss of time
If a sodium channel blocker is administered alone, then the treatment protocol is simple, but the conversion time is prolonged
Solution Approach 1:
The potassium channel blocker is administered before or concurrently with the sodium channel blocker to pre-condition the cardiac tissue. This preliminary action modifies the repolarization phase and increases sodium channel availability, thereby accelerating the subsequent effectiveness of the sodium channel blocker in terminating AF and reducing overall conversion time.
3Reliability
If a sodium channel blocker is administered alone, then the risk of side effects is lower, but the ability to prevent recurrence is reduced
Solution Approach 1:
The combination therapy modifies multiple electrophysiological parameters simultaneously - sodium channel blockade affects depolarization velocity while potassium channel blockade extends repolarization duration. This multi-parameter modification creates a more favorable electrophysiological environment for preventing AF recurrence, allowing for lower doses of each individual drug and thereby reducing side effect risks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases AF termination by 20-100% and reduces ventricular proarrhythmia risk, while shortening conversion time and preventing recurrence.
Implementation Method 1
elevation of extracellular potassium ([K+]0) depolarizes the cardiac resting membrane potential (RMP) and that depolarization of the RMP augments the ability of sodium channel blockers to inhibit sodium channel current (INa)
Data Source
AI summary
Compositions and methods for safe and effective treatment for cardiac arrhythmias via increasing [K+]0 and administering a sodium channel blocker are disclosed. In certain embodiments, the method includes administering a composition comprising sodium tablets and flecainide to a subject.